KSQ: Widescreen CRISPR

How KSQ is using its CRISPRomics technology to identify cancer targets

KSQ Therapeutics Inc. is developing therapies using its CRISPRomics technology to identify cancer and immuno-oncology targets by screening all human genes in cancer cell lines and T cells.

The company emerged from stealth in 2017 with a $76 million round led by Flagship Pioneering, with participation from fellow founding investor Polaris Partners, and a leadership team that includes Genzyme veteran David Meeker as president

Read the full 632 word article

How to gain access

Continue reading with a
two-week free trial.